摘要
The traditional strengths of biotechnology research organizations (e.g. molecular biology, protein engineering, cell biology, protein expression, antibody identification and humanization) can be applied to the rational identification of small molecule leads. These efforts will augment the more traditional approaches of large pharma organizations.